Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Novavax (Nasdaq: NVAX) will participate in the 44th Annual J.P. Morgan Healthcare Conference.
The company will present on Wednesday, January 14, 2026 at 4:30 p.m. Pacific Time in San Francisco, CA. A live webcast will be available on the company's Events & Presentations page at ir.novavax.com, and a replay will be available for 30 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction – NVAX
In the Jan 7 session, NVAX gained 2.42%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Nov 12 | Conference participation | Neutral | -3.2% | Announcement of Jefferies London Healthcare Conference fireside chat and webcast access. |
| Nov 06 | Earnings update | Neutral | -1.3% | Q3 2025 financial results with $70M revenue and $202M net loss disclosed. |
| Nov 04 | Collaboration milestone | Positive | -5.1% | Completion of U.S. marketing authorization transfer to Sanofi triggering $25M milestone. |
| Oct 30 | Earnings scheduling | Neutral | +0.6% | Notice of upcoming Q3 2025 earnings call and webcast logistics for investors. |
| Oct 22 | Cost reduction move | Positive | -1.5% | Maryland site consolidation expected to generate $60M proceeds and $230M savings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent NVAX news—including milestones, earnings, and corporate actions—has often been followed by mild negative price reactions, even when announcements appeared operationally positive or strategic.
Over the past few months, Novavax has focused on strategic realignment and partnership monetization. Site consolidation in Maryland targeted $230M in future savings and generated $60M in proceeds. Collaboration with Sanofi around Nuvaxovid produced $225M in milestones year‑to‑date 2025. Q3 2025 results showed revenue of $70M and a net loss of $202M, alongside substantial non‑cash charges. Conference participation, such as the November 2025 Jefferies event and the newly announced J.P. Morgan appearance, fits a pattern of active investor outreach following these operational updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Details: | |
Presentation | |
Date: | Wednesday, January 14, 2026 |
Time: | 4:30 p.m. Pacific Time |
Location: | |
A webcast of the presentation will be available on the Events & Presentations page of the Company's website at ir.novavax.com. A replay of the webcast will be available for 30 days.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) tackles some of the world's most pressing health challenges with its scientific expertise in vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M® adjuvant. The Company's growth strategy seeks to optimize its existing partnerships and expand access to its proven technology platform via research and development innovation, organic portfolio expansion in infectious disease and beyond, and forging new partnerships and collaborations with other companies. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Luis Sanay, CFA
240-268-2022
ir@novavax.com
Media
Yvonne Sprow
240-720-7804
media@novavax.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-the-44th-annual-jp-morgan-healthcare-conference-302654454.html
SOURCE Novavax, Inc.